Why the study?
Does chloroquine reduce arrhythmia risk in KCNJ2-linked short QT syndrome (SQT3) models?
Does chloroquine reduce arrhythmia risk in KCNJ2-linked short QT syndrome (SQT3) models?
Computational modeling suggests chloroquine may be a potential therapeutic agent for KCNJ2-linked short QT syndrome (SQT3) by reducing arrhythmia risk.
May support chloroquine for SQT3; hypothesis-generating from tissue models and should not change practice.
, prolonged APD, and decreased the maximum voltage heterogeneity. Chloroquine prolonged QT interval and declined the T-wave amplitude. Although chloroquine reduced tissue's temporal vulnerability, it increased the minimum substrate size necessary for sustaining re-entry. The actions of chloroquine decreased arrhythmia risk, due to the reduced tissue vulnerability, prolonged ERP and wavelength of re-entrant excitation waves, which in combination prevented and terminated re-entry in the tissue models. In conclusion, the results of this study provide new evidence that the anti-arrhythmic effects of chloroquine on SQT3 and, by extension, to the possibility that chloroquine may be a potential therapeutic agent for SQT3 treatment.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: